Cargando…

Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance: A case report

RATIONALE: Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, is an aggressive tumor with very poor prognosis. Regorafenib was the first agent to show a survival benefit over placebo in patients who showed progression while being treated with sorafenib, but it remains an unsat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Hong, Yang, Xi, Zhao, Yaqin, Yi, Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531185/ https://www.ncbi.nlm.nih.gov/pubmed/31096541 http://dx.doi.org/10.1097/MD.0000000000015755

Ejemplares similares

Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210
por: Chen, Xuelian, et al.
Publicado: (2019)

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210), a novel anti‐PD‐1 antibody
por: Wang, Xi, et al.
Publicado: (2019)

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
por: Mo, Hongnan, et al.
Publicado: (2018)

Anti-PD1 ‘SHR-1210ʹ aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement
por: Finlay, William J.J., et al.
Publicado: (2018)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Publicado: (2020)

The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report
por: Zhu, Hong, et al.
Publicado: (2018)

SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
por: Mu, Lan, et al.
Publicado: (2021)

Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model()()
por: Shi, Shengbin, et al.
Publicado: (2018)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Efficacy and Safety of Second-line Treatments in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Meta-analysis
por: An, Limin, et al.
Publicado: (2021)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
por: Zhou, Jinhan, et al.
Publicado: (2021)

Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report
por: Zhu, Hong, et al.
Publicado: (2019)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Characterization of a monoclonal antibody to L1210 leukaemia.
por: Testorelli, C., et al.
Publicado: (1982)

Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines
por: Zhang, Zhi, et al.
Publicado: (2020)

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib
por: da Fonseca, Leonardo Gomes, et al.
Publicado: (2018)

Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance
por: Zou, Xinhua, et al.
Publicado: (2023)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
por: Takada, Hitomi, et al.
Publicado: (2019)

Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Han, Peng, et al.
Publicado: (2017)

Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review
por: Long, Xin, et al.
Publicado: (2022)

Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
por: Yoo, Jeong-Ju, et al.
Publicado: (2019)

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint
por: Chen, Jiang, et al.
Publicado: (2016)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
por: Chen, San-Chi, et al.
Publicado: (2022)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol–sorafenib hybrids
por: Awasthi, Bhuwan Prasad, et al.
Publicado: (2021)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma
por: Marta, Guilherme Nader, et al.
Publicado: (2021)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma
por: Samadaei, Mahzeiar, et al.
Publicado: (2022)

Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
por: Liu, Jianhua, et al.
Publicado: (2017)

Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2021)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
por: Kelley, Robin Kate, et al.
Publicado: (2020)

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)

Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study
por: Li, Jian-Xu, et al.
Publicado: (2022)

Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration
por: Ding, Lijuan, et al.
Publicado: (2023)

Cytostatic Effect of Deoxyspergualin on a Murine Leukemia Cell Line L1210
por: Hiratsuka, Masaharu, et al.
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_knvrhndodo017bs6r422b7mk4i